Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(16):1167; doi:10.1093/jnci/dji282
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Recommendations for Tumor Marker Prognostic Studies

Published tumor marker study articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. To improve the quality of marker research reporting, McShane et al. (p. 1180) have developed guidelines for the reporting of tumor marker studies, as recommended by the National Cancer Institute–European Organization for Research and Treatment of Cancer First International Meeting on Cancer Diagnostics in 2000. The guidelines identify information about the study design, pre-planned hypotheses, patient and specimen characteristics, assay methods, and statistical methods that should be . . . [Full Text of this Article]

Role of Detection in Predicting Breast Cancer Survival

Differential Effects of Gefitinib and Cetuximab in NSCLC

Cancer in Men With Klinefelter Syndrome

Disparities in the Receipt of Treatment for Colon Cancer

Cetuximab Therapy and Symptomatic Hypomagnesemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?